Posts

Showing posts from June, 2014

.TXTM Alert! ✈ Exponential Growth in the Auto Dealer Market

Image
Subject: TXTM Alert! ✈ Exponential Growth in the Auto Dealer Market View this email online if it doesn't display correctlyProtext Mobility
(TXTM)
Huge Exponential Growth
in the Auto Dealer Market!
, Develops Innovative Products and Solutions for the Mobile Communications Market

Protext Mobility (TXTM) is a publicly traded premium mobile applications developer.

We provide innovative solutions to the fast-growing mobile consumer market.

Our goal is to address mobile messaging market opportunities with novel, …

Oriens (OTHM) ☀ Hotel PURE is a Million Dollar Brand

Image
Subject: Oriens (OTHM) ☀ Hotel PURE is a Million Dollar Brand View this email online if it doesn't display correctlyOriens (OTHM)Hotel PURE is a
Multi-Million Dollar Hotel Brand   
Oriens Travel & Hotel Management Corp, provides proprietary technology, marketing solutions, infrastructure and branding services to Hotel operators.
 Oriens’ booking engine technology and hotel branding services, expands a property’s International exposure and recognition, creates a new and improved core structure and greatly increases occupancy rates an…

Media Advisory: GenSpera 2014 BIO International Presentation Available

Image
Media Advisory: GenSpera 2014 BIO International Presentation Available


http://finance.yahoo.com/news/media-advisory-genspera-2014-bio-120000165.html

GenSpera, Inc. (GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.

Summary:

G-202 Data in Hepatocellular (HCC) Patients (Ph I and Ph II)
All patients previously progressed on, or were intolerant of, sorafenib
Outstanding clinical safety profile
Well tolerated with easily managed and predictable side effects
No effect on bone marrow!
80% of patients with stable disease (no tumor growth) at two months
50% of patients with stable disease for >/= 4 months
Long-term disease stabilization (…